Alnylam Pharmaceuticals (ALNY) Operating Income (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Operating Income (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - |
| 10 | Alterity Therapeutics | 29.20 Bn | 29.20 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.95% |
| Dec 31, 2025 | -64.21% |
| Sep 30, 2025 | 2,371.63% |
| Jun 30, 2025 | -189.61% |
| Mar 31, 2025 | 117.19% |
| Dec 31, 2024 | -36.74% |
| Sep 30, 2024 | -258.20% |
| Jun 30, 2024 | 211.92% |
| Mar 31, 2024 | 62.69% |
| Dec 31, 2023 | -154.43% |
| Sep 30, 2023 | 193.05% |
| Jun 30, 2023 | -53.42% |
| Mar 31, 2023 | 20.57% |
| Dec 31, 2022 | 26.91% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -30.64% |
| Mar 31, 2022 | 24.58% |
| Dec 31, 2021 | -7.09% |
| Sep 30, 2021 | -24.30% |
| Jun 30, 2021 | 21.53% |